Benzinga’s Top Ratings Upgrades, Downgrades For January 17, 2023
Upgrades For Casa Systems Inc (NASDAQ:CASA), Northland Capital Markets upgraded the previous rating of Market Perform to Outperform.…
Ascendiant Capital Initiates Coverage On Vivos Therapeutics with Buy Rating, Announces Price Target of $2.5
Ascendiant Capital analyst Edward Woo initiates coverage on Vivos Therapeutics (NASDAQ:VVOS) with a Buy rating and announces Price Target of $2.5.
Why Vivos Therapeutics Shares Are Nosediving
Vivos Therapeutics Inc (NASDAQ: VVOS) shares are trading lower by 9.57% to $1.70 Thursday morning after the company priced an $8 million private placement at $1.20 per unit.
Dow Gains 150 Points After Fed Minutes
U.S. stocks traded higher toward the end of trading, following the release of minutes from the FOMC meeting.
Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Vivos Therapeutics, Inc. (NASDAQ: VVOS) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive sleep apnea.
Nasdaq Rises Over 100 Points; Crude Oil Drops Sharply
U.S. stocks extended gains midway through trading, with the Dow Jones gaining around 250 points on Wednesday ahead of the release of minutes from the Fed's meeting.
Why Horizon Global Shares Are Trading Higher By Over 340%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Horizon Global Corporation (NYSE: HZN) shares surged 341% to $1.7161 after the company announced it will be acquired by First Brands Group.
Why Venus Concept Shares Are Trading Higher By Over 63%? Here Are 58 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Sintx Technologies, Inc. (NASDAQ: SINT) shares climbed 81.4% to $13.55 after the company was awarded Phase I contract for $150,000 from the Missile Defense Agency for electrochemical machining.
CORRECTION: Vivos Therapeutics Q3 EPS $(0.26), Same YoY, Sales $4.25M Beat $3.72M Estimate
Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.26) per share. This is unchanged from the same period last year. The company reported quarterly sales of $4.25 million which beat the analyst consensus